This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Antibiotics in sinusitis

Authoring team

The following antibiotics are recommended for the treatment of acute sinusitis:

  • for adults aged 18 years and over
    • first choice
      • Phenoxymethylpenicillin - 500 mg four times a day for 5 days
    • first choice if systemically very unwell, symptoms and signs of a more serious illness or condition, or at high risk of complications
      • Co-amoxiclav - 500/125 mg three times a day for 5 days
    • alternative first choices for penicillin allergy or intolerance
      • Doxycycline - 200 mg on first day, then 100 mg once a day for 4 days (5-day course in total)
      • Clarithromycin - 500 mg twice a day for 5 days
      • Erythromycin (in pregnancy) - 250 mg to 500 mg four times a day or 500 mg to 1000 mg twice a day for 5 days
    • second choice (worsening symptoms on first choice taken for at least 2 to 3 days)
      • Co-amoxiclav - 500/125 mg three times a day for 5 days
        • if co-amoxiclav has been used as first choice, consult local microbiologist for advice on second choice
    • alternative second choice for penicillin allergy or intolerance, or worsening symptoms on second choice taken for at least 2 to 3 days
      • consult local microbiologist
  • for children and young people under 18 years
    • first choice
      • Phenoxymethylpenicillin
        • 1 to 11 months, 62.5 mg four times a day for 5 days
        • 1 to 5 years, 125 mg four times a day for 5 days
        • 6 to 11 years, 250 mg four times a day for 5 days
        • 12 to 17 years, 500 mg four times a day for 5 days
    • first choice if systemically very unwell, symptoms and signs of a more serious illness or condition, or at high risk of complications
      • Co-amoxiclav
        • 1 to 11 months, 0.25 ml/kg of 125/31 suspension three times a day for 5 days
        • 1 to 5 years, 5 ml of 125/31 suspension three times a day or 0.25 ml/kg of 125/31 suspension three times a day for 5 days
        • 6 to 11 years, 5 ml of 250/62 suspension three times a day or 0.15 ml/kg of 250/62 suspension three times a day for 5 days
        • 12 to 17 years, 250/125 mg three times a day or 500/125 mg three times a day for 5 days
    • alternative first choice for penicillin allergy or intolerance
      • Clarithromycin
        • Under 8 kg, 7.5 mg/kg twice a day for 5 days
        • 8 to 11 kg, 62.5 mg twice a day for 5 days
        • 12 to 19 kg, 125 mg twice a day for 5 days
        • 20 to 29 kg, 187.5 mg twice a day for 5 days
        • 30 to 40 kg, 250 mg twice a day for 5 days
        • 12 to 17 years, 250 mg twice a day or 500 mg twice a day for 5 days
      • Doxycycline
        • is contraindicated in children under 12 years
        • 12 to 17 years, 200 mg on first day, then 100 mg once a day for 4 days (5-day course in total)
    • second choice (worsening symptoms on first choice taken for at least 2 to 3 days)
      • Co-amoxiclav - as above
        • If co-amoxiclav used as first choice, consult local microbiologist for advice on second choice
    • alternative second choice for penicillin allergy or intolerance, or worsening symptoms on second choice taken for at least 2 to 3 days
      • consult local microbiologist

Reference:

  1. National Institute for Health and Care Excellence (NICE) 2017. Sinusitis (acute): antimicrobial prescribing
  2. Public Health England (June 2021). Managing common infections: guidance for primary care

Create an account to add page annotations

Add information to this page that would be handy to have on hand during a consultation, such as a web address or phone number. This information will always be displayed when you visit this page

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.